Effects of anti-proliferative lichen metabolite, protolichesterinic acid on fatty acid synthase, cell signalling and drug response in breast cancer cells

Phytomedicine

Volumn 21, Issue 12, 2014, Pages 1717-1724

  Bessadóttir, Margrét ^a   Skúladóttir, Edda Á ^a   Gowan, Sharon ^b   Eccles, Suzanne ^b   Ómarsdóttir, Sesselja ^a   Ögmundsdóttir, Helga M ^a  

^a UNIVERSITY OF ICELAND   (Iceland)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Breast cancer; FASN; HER2; Lichen; Protolichesterinic acid

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FATTY ACID SYNTHASE; LAPATINIB; NATURAL PRODUCT; PROTOLICHESTERINIC ACID; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; GAMMA BUTYROLACTONE; QUINAZOLINE DERIVATIVE;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CELL VIABILITY ASSAY; CHEMICAL STRUCTURE; DRUG EFFECT; DRUG ISOLATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INTRACELLULAR SIGNALING; LICHEN (ORGANISM); PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; FEMALE; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

4-BUTYROLACTONE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; FATTY ACID SYNTHASES; FEMALE; HUMANS; LICHENS; MOLECULAR STRUCTURE; QUINAZOLINES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84907186638     PISSN: 09447113     EISSN: 1618095X     Source Type: Journal    
DOI: 10.1016/j.phymed.2014.08.006     Document Type: Article

References (63)

1. H.N. Abramson The lipogenesis pathway as a cancer target J. Med. Chem. 54 2011 5615 5638
2. J. Baselga, J. Cortes, S.B. Kim, S.A. Im, R. Hegg, Y.H. Im, L. Roman, J.L. Pedrini, T. Pienkowski, A. Knott, E. Clark, M.C. Benyunes, G. Ross, and S.M. Swain Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N. Engl. J. Med. 366 2012 109 119
3. Bessadóttir, M., Eiríksson, F.F., Becker, S., Ögmundsdóttir, M.H., Ómarsdóttir, S., Thorsteinsdóttir, M., Ögmundsdóttir, H.M. Anti-proliferative and pro-apoptotic effects of lichen-derived compound protolichesterinic acid are not mediated by its lipoxygenase-inhibitory activity. (in manuscript).
4. K.L. Blackwell, H.J. Burstein, A.M. Storniolo, H.S. Rugo, G. Sledge, G. Aktan, C. Ellis, A. Florance, S. Vukelja, J. Bischoff, J. Baselga, and J. O'Shaughnessy Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study J. Clin. Oncol. 30 2012 2585 2592
5. B.G. Blair, A. Bardelli, and B.H. Park Somatic alterations as the basis for resistance to targeted therapies J. Pathol. 232 2014 244 254
6. I. Bozic, J.G. Reiter, B. Allen, T. Antal, K. Chatterjee, P. Shah, Y.S. Moon, A. Yaqubie, N. Kelly, D.T. Le, E.J. Lipson, P.B. Chapman, L.A. Diaz Jr., B. Vogelstein, and M.A. Nowak Evolutionary dynamics of cancer in response to targeted combination therapy Elife 2 2013 e00747
7. F. Brisdelli, M. Perilli, D. Sellitri, M. Piovano, J.A. Garbarino, M. Nicoletti, A. Bozzi, G. Amicosante, and G. Celenza Cytotoxic activity and antioxidant capacity of purified lichen metabolites: an in vitro study Phytother. Res. 27 2013 431 437
8. F. Bucar, I. Schneider, H. Ogmundsdottir, and K. Ingolfsdottir Anti-proliferative lichen compounds with inhibitory activity on 12(S)-HETE production in human platelets Phytomedicine 11 2004 602 606
9. D. Cameron, M. Casey, C. Oliva, B. Newstat, B. Imwalle, and C.E. Geyer Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial Oncologist 15 2010 924 934
10. G. Casey, M. Lo-Hsueh, M.E. Lopez, B. Vogelstein, and E.J. Stanbridge Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene Oncogene 6 1991 1791 1797
11. D. Chalbos, M. Chambon, G. Ailhaud, and H. Rochefort Fatty acid synthetase and its mRNA are induced by progestins in breast cancer cells J. Biol. Chem. 262 1987 9923 9926
12. T.C. Chou Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol. Rev. 58 2006 621 681
13. F.J. Esteva, D. Yu, M.C. Hung, and G.N. Hortobagyi Molecular predictors of response to trastuzumab and lapatinib in breast cancer Nat. Rev. Clin. Oncol. 7 2010 98 107
14. S. Haraldsdottir, E. Guolaugsdottir, K. Ingolfsdottir, and H.M. Ogmundsdottir Anti-proliferative effects of lichen-derived lipoxygenase inhibitors on twelve human cancer cell lines of different tissue origin in vitro Planta Med. 70 2004 1098 1100
15. D. Horhant, Lamer A-CL, J. Boustie, P. Uriac, and N. Gouault Separation of a mixture of paraconic acids from Cetraria islandica (L.) Ach. employing a fluorous tag - catch and release strategy Tetrahedron Lett. 48 2007 6031 6033
16. K. Ingolfsdottir, W. Breu, S. Huneck, G.A. Gudjonsdottir, B. Muller-Jakic, and H. Wagner In vitro inhibition of 5-lipoxygenase by protolichesterinic acid from Cetraria islandica Phytomedicine 1 1994 187 191
17. K. Ingolfsdottir, G.A. Chung, V.G. Skulason, S.R. Gissurarson, and M. Vilhelmsdottir Antimycobacterial activity of lichen metabolites in vitro Eur. J. Pharm. Sci. 6 1998 141 144
18. K. Ingolfsdottir, M.A. Hjalmarsdottir, A. Sigurdsson, G.A. Gudjonsdottir, A. Brynjolfsdottir, and O. Steingrimsson In vitro susceptibility of Helicobacter pylori to protolichesterinic acid from the lichen Cetraria islandica Antimicrob. Agents Chemother. 41 1997 215 217
19. Q. Jin, L.X. Yuan, D. Boulbes, J.M. Baek, Y.N. Wang, D. Gomez-Cabello, D.H. Hawke, S.C. Yeung, M.H. Lee, G.N. Hortobagyi, M.C. Hung, and F.J. Esteva Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells Breast Cancer Res. 12 2010 R96
20. G.E. Konecny, M.D. Pegram, N. Venkatesan, R. Finn, G. Yang, M. Rahmeh, M. Untch, D.W. Rusnak, G. Spehar, R.J. Mullin, B.R. Keith, T.M. Gilmer, M. Berger, K.C. Podratz, and D.J. Slamon Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells Cancer Res. 66 2006 1630 1639
21. F.P. Kuhajda, K. Jenner, F.D. Wood, R.A. Hennigar, L.B. Jacobs, J.D. Dick, and G.R. Pasternack Fatty acid synthesis: a potential selective target for antineoplastic therapy Proc. Natl. Acad. Sci. U. S. A. 91 1994 6379 6383
22. F.P. Kuhajda, E.S. Pizer, J.N. Li, N.S. Mani, G.L. Frehywot, and C.A. Townsend Synthesis and antitumor activity of an inhibitor of fatty acid synthase Proc. Natl. Acad. Sci. U. S. A. 97 2000 3450 3454
23. C. Kumar-Sinha, K.W. Ignatoski, M.E. Lippman, S.P. Ethier, and A.M. Chinnaiyan Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis Cancer Res. 63 2003 132 139
24. K.C. Kumar, and K. Muller Lichen metabolites. 1. Inhibitory action against leukotriene B4 biosynthesis by a non-redox mechanism J. Nat. Prod. 62 1999 817 820
25. H. Liu, J.Y. Liu, X. Wu, and J.T. Zhang Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker Int. J. Biochem. Mol. Biol. 1 2010 69 89
26. R. Lupu, and J.A. Menendez Pharmacological inhibitors of Fatty Acid Synthase (FASN) - catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Curr. Pharm. Biotechnol. 7 2006 483 493
27. J.A. Menendez, R. Lupu, and R. Colomer Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER-2/neu-overexpressing human breast cancer cells to docetaxel (taxotere) Breast Cancer Res. Treat. 84 2004 183 195
28. J.A. Menendez, R. Lupu, and R. Colomer Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancer Drug News Perspect. 18 2005 375 385
29. J.A. Menendez, I. Mehmi, E. Atlas, R. Colomer, and R. Lupu Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB Int. J. Oncol. 24 2004 591 608
30. J.A. Menendez, B.P. Oza, R. Colomer, and R. Lupu The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival Int. J. Oncol. 26 2005 1507 1515
31. J.A. Menendez, L. Vellon, and R. Lupu Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene Ann. Oncol. 16 2005 1253 1267
32. J.A. Menendez, L. Vellon, I. Mehmi, B.P. Oza, S. Ropero, R. Colomer, and R. Lupu Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells Proc. Natl. Acad. Sci. U. S. A. 101 2004 10715 10720
33. T. Migita, S. Ruiz, A. Fornari, M. Fiorentino, C. Priolo, G. Zadra, F. Inazuka, C. Grisanzio, E. Palescandolo, E. Shin, C. Fiore, W. Xie, A.L. Kung, P.G. Febbo, A. Subramanian, L. Mucci, J. Ma, S. Signoretti, M. Stampfer, W.C. Hahn, S. Finn, and M. Loda Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer J. Natl. Cancer Inst. 101 2009 519 532
34. M.S. Mohd Sharial, J. Crown, and B.T. Hennessy Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer Ann. Oncol. 23 2012 3007 3016
35. R. Nahta, D. Yu, M.C. Hung, G.N. Hortobagyi, and F.J. Esteva Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer Nat. Clin. Pract. Oncol. 3 2006 269 280
36. M. Notarnicola, V. Tutino, M. Calvani, D. Lorusso, V. Guerra, and M.G. Caruso Serum levels of fatty acid synthase in colorectal cancer patients are associated with tumor stage J. Gastrointest. Cancer 43 2012 508 511
37. H.M. Ogmundsdottir, G.M. Zoega, S.R. Gissurarson, and K. Ingolfsdottir Anti-proliferative effects of lichen-derived inhibitors of 5-lipoxygenase on malignant cell-lines and mitogen-stimulated lymphocytes J. Pharm. Pharmacol. 50 1998 107 115
38. S. Omura The antibiotic cerulenin, a novel tool for biochemistry as an inhibitor of fatty acid synthesis Bacteriol. Rev. 40 1976 681 697
39. H. Orita, J. Coulter, E. Tully, F.P. Kuhajda, and E. Gabrielson Inhibiting fatty acid synthase for chemoprevention of chemically induced lung tumors Clin. Cancer Res. 14 2008 2458 2464
40. T. Pengsuparp, L. Cai, H. Constant, H.H. Fong, L.Z. Lin, A.D. Kinghorn, J.M. Pezzuto, G.A. Cordell, K. Ingolfsdottir, and H. Wagner Mechanistic evaluation of new plant-derived compounds that inhibit HIV-1 reverse transcriptase J. Nat. Prod. 58 1995 1024 1031
41. H.L. Perez, P.M. Cardarelli, S. Deshpande, S. Gangwar, G.M. Schroeder, G.D. Vite, and R.M. Borzilleri Antibody-drug conjugates: current status and future directions Drug Discov. Today 19 2014 869 881
42. E.S. Pizer, C. Jackisch, F.D. Wood, G.R. Pasternack, N.E. Davidson, and F.P. Kuhajda Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells Cancer Res. 56 1996 2745 2747
43. E.S. Pizer, J. Thupari, W.F. Han, M.L. Pinn, F.J. Chrest, G.L. Frehywot, C.A. Townsend, and F.P. Kuhajda Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts Cancer Res. 60 2000 213 218
44. T. Puig, C. Turrado, B. Benhamu, H. Aguilar, J. Relat, S. Ortega-Gutierrez, G. Casals, P.F. Marrero, A. Urruticoechea, D. Haro, M.L. Lopez-Rodriguez, and R. Colomer Novel inhibitors of fatty acid synthase with anticancer activity Clin. Cancer Res. 15 2009 7608 7615
45. A. Russo, S. Caggia, M. Piovano, J. Garbarino, and V. Cardile Effect of vicanicin and protolichesterinic acid on human prostate cancer cells: role of Hsp70 protein Chem. Biol. Interact. 195 2012 1 10
46. O. Sahin, Q. Wang, S.W. Brady, K. Ellis, H. Wang, C.C. Chang, Q. Zhang, P. Priya, R. Zhu, S.T. Wong, M.D. Landis, W.J. Muller, F.J. Esteva, J. Chang, and D. Yu Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors Cell Res. 24 2014 542 559
47. M.A. Sendur, S. Aksoy, and K. Altundag Cardiotoxicity of novel HER2-targeted therapies Curr. Med. Res. Opin. 29 2013 1015 1024
48. G. Shrestha, and L.L. St Clair Lichens: a promising source of antibiotic and anticancer drugs Phytochem. Rev. 12 2013 229 244
49. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
50. O. Sticher [On the antibacterial effectiveness of Lichen islandicus with special reference to the composition. 2] Pharm. Acta Helv. 40 1965 483 495
51. S.M. Swain, S.B. Kim, J. Cortes, J. Ro, V. Semiglazov, M. Campone, E. Ciruelos, J.M. Ferrero, A. Schneeweiss, A. Knott, E. Clark, G. Ross, M.C. Benyunes, and J. Baselga Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study Lancet Oncol. 14 2013 461 471
52. C. Turrado, T. Puig, J. Garcia-Carceles, M. Artola, B. Benhamu, S. Ortega-Gutierrez, J. Relat, G. Oliveras, A. Blancafort, D. Haro, P.F. Marrero, R. Colomer, and M.L. Lopez-Rodriguez New synthetic inhibitors of fatty acid synthase with anticancer activity J. Med. Chem. 55 2012 5013 5023
53. A. Vazquez-Martin, R. Colomer, J. Brunet, R. Lupu, and J.A. Menendez Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells Cell Prolif. 41 2008 59 85
54. A. Vazquez-Martin, R. Colomer, J. Brunet, and J.A. Menendez Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells Int. J. Oncol. 31 2007 769 776
55. A. Vazquez-Martin, J.M. Fernandez-Real, C. Oliveras-Ferraros, J.M. Navarrete, B. Martin-Castillo, S. Del Barco, J. Brunet, and J.A. Menendez Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients Int. J. Oncol. 35 2009 1369 1376
56. L. Vidarsdottir, G. Steingrimsdottir, S.K. Bodvarsdottir, H.M. Ogmundsdottir, and J.E. Eyfjord Sensitivity of BRCA2 mutated human cell lines to Aurora kinase inhibition Invest. New Drugs 30 2012 425 434
57. A. Vincent-Salomon, C. Lucchesi, N. Gruel, V. Raynal, G. Pierron, R. Goudefroye, F. Reyal, F. Radvanyi, R. Salmon, J.P. Thiery, X. Sastre-Garau, B. Sigal-Zafrani, A. Fourquet, and O. Delattre Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast Clin. Cancer Res. 14 2008 1956 1965
58. H.Q. Wang, D.A. Altomare, K.L. Skele, P.I. Poulikakos, F.P. Kuhajda, A. Di Cristofano, and J.R. Testa Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells Oncogene 24 2005 3574 3582
59. Y. Wang, F.P. Kuhajda, J.N. Li, E.S. Pizer, W.F. Han, L.J. Sokoll, and D.W. Chan Fatty acid synthase (FAS) expression in human breast cancer cell culture supernatants and in breast cancer patients Cancer Lett. 167 2001 99 104
60. W. Xia, R.J. Mullin, B.R. Keith, L.H. Liu, H. Ma, D.W. Rusnak, G. Owens, K.J. Alligood, and N.L. Spector Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways Oncogene 21 2002 6255 6263
61. C.S. Yang, X. Wang, G. Lu, and S.C. Picinich Cancer prevention by tea: animal studies, molecular mechanisms and human relevance Nat. Rev. Cancer 9 2009 429 439
62. Y.A. Yang, W.F. Han, P.J. Morin, F.J. Chrest, and E.S. Pizer Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase Exp. Cell Res. 279 2002 80 90
63. S. Yoon, M.Y. Lee, S.W. Park, J.S. Moon, Y.K. Koh, Y.H. Ahn, B.W. Park, and K.S. Kim Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells J. Biol. Chem. 282 2007 26122 26131